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Abstract 
MALDI MS profiling has attracted considerable interest from the clinical community as a 
potentially valuable alternative to other diagnostic and prognostic tools by analysing 
biomarkers from easily available body fluids such as blood serum.  Despite the numerous 
reports on MALDI MS profiling of human serum there is only scarce information on the 
identity of the biomolecular species making up these profiles, particularly in the mass range 
of larger peptides.  Here we provide a methodology for MALDI MS profiling peak 
identification and an extensive list of peak identities up to 10 kDa obtained from human 
blood serum.  The list of identities obtained so far comprises more than 90 entries.  In 
addition to peptides published in other lists, we have also identified high-molecular weight 
peptides with masses above 5 kDa.  Some of the identifications were related to endogenous 
lipids.  Amongst the peptide identifications various modifications such as phosphorylation 
were detected.  The overlap with the few other peptide lists published so far was found to be 
limited and hence our list significantly extends the number of identified peptides commonly 
found in MALDI MS profiling of human blood serum.  With the data from this study it is 
further shown that lists of endogenous serum peptides can only be useful for MALDI MS 
profiling if the peak identifications can be directly linked to the MALDI MS profiles.  A list of 
identifications of MALDI MS profile peaks from human blood serum, compiled from published 
data and this work, is presented. 
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Introduction 
There has been great interest in exploiting simple MALDI MS profiling for the analysis of 
crude or little purified human serum or plasma samples for clinical diagnostics 1-3.  However, 
through the many studies that have been conducted in this area it has become apparent that 
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there are far more challenges related to its applicability to disease diagnosis than initially 
thought.  The technical bias in the analytical read-out and the ultimate sensitivity and 
diagnostic accuracy of MALDI MS profiling are of major concern 4-7.  The wide range of 
abundances and the complexity of the endogenous molecular components in blood further 
aggravate the analytical situation 2.  However, there have been now further reports 
substantiating the claim that MALDI MS profiling can indeed be a tool for disease (outcome) 
classification8 and biomarker discovery9. 
 
Thus, it is surprising that little is known about most of these potential biomarkers as typically 
no structural identification is undertaken.  This presents a serious limitation for alternative 
quantification and validation of potentially discriminatory peaks and restricts biomarker assay 
development, including immunoassays, that might potentially overcome some of the above 
analytical limitations of MALDI MS profiling. 
 
MALDI MS profiling focuses on the reproducible, rapid and inexpensive acquisition of MS 
peak patterns that can be used for discriminative analysis as needed in population screening 
or clinical triage.  Thus, it is different to in-depth analyses of the human blood serum or 
plasma where peak identification is an objective and many thousands of peptides and 
proteins have been identified 10-12. 
 
As with in-depth analyses, peptide identification of MS profile peaks is ideally undertaken at 
the same time as MS profiling with the same sample on the same instrument, using the MS 
profile for precursor ion determination and directly switching to MS/MS mode for peptide 
sequencing.  Employing MALDI, however, peptide sequencing is more challenging and 
usually less sensitive and informative for identification purposes than ESI-LC-MS/MS.  Thus, 
the reported long lists of identified peptides or proteins present in serum or plasma are 
typically based on ESI-LC-MS/MS (mostly in combination with extensive pre-fractionation) 
and without any relation to MALDI MS profiles, including the lists that provide identifications 
in the commonly recorded low molecular weight range of these profiles, i.e. <10 kDa 13-15.  
Indeed, only a few identifications of MALDI MS profile peaks have been reported so far.  The 
most comprehensive list of peptide identifications obtained from human blood serum and 
related to MALDI MS profile peaks was reported by Villanueva et al. 16, although it provides 
only identification of peaks below 4 kDa.  For blood plasma, Koomen et al. reported a list of 
249 sequenced plasma profile peptides with a maximum mass of 5.2 kDa 17. 
 
Materials and methods 
Venous blood samples were collected from healthy persons recruited at different centres as 
part of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) or 
United Kingdom Ovarian Cancer Population Study (UKOPS) (for details see Timms et al., 
Clin. Chem., in press).  The entire study was approved by the local ethics committee and 
written informed consent was obtained from all donors. 
 
For UKOPS, blood was collected in 10mL-Vacutainer (‘red-top’) tubes (Becton Dickinson, 
Oxford, UK; #367985).  After phlebotomy, the tubes were inverted 5 times and left at room 
temperature in a vertical position to clot for 1 hr.  Samples were then placed on ice for no 
more than 2 hrs, centrifuged at 1,500 g for 10 min at room temperature, aliquoted into sterile 
10mL-tubes (Sarstedt, Leicester, UK) and frozen at -80°C.  For UKCTOCS, different 
consumables were used and the clotting time was between 8 and 56 hours before spinning, 
strawing and freezing.  All samples were transported to the Institute for Women’s Health 
Laboratory at UCL on dry ice and thawed at room temperature for 30 min.  The samples 
were then mixed by gentle inversion and aliquoted into bar-coded straws, re-frozen at -80°C 
for 24 hours and then transferred to liquid N2 for long-term storage. 
 
For initial MALDI-TOF MS profiling, serum samples were taken from long-term storage and 
prepared according to a protocol we have reported elsewhere (see 5 for details).  Briefly, 
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polypeptides were enriched from 5 µL of serum using a semi-automated protocol based on 
reversed phase pre-packed tips (C18 ZipTips®).  A CyBi®-Disk robot (CyBio AG, Jena, 
Germany) equipped with a 96-piston head for 25µL-tips was adapted and used for this 
purpose.  After C18 ZipTip® purification, enriched polypeptides were eluted from the 
ZipTips®, and 2 µL from the eluate were mixed with CHCA matrix and spotted onto a 600µm-
AnchorChip target plate (Bruker Daltonics, Bremen, Germany) for analysis on an Ultraflex II 
MALDI-TOF/TOF mass spectrometer (Bruker Daltonics), using FlexAnalysis v3.0 and 
ClinProTools v2.1 software (Bruker Daltonics) for further data analysis.  The remaining 5 µL 
of the eluate were immediately stored at -80C until being used for further analysis. 
 
Peak identifications were obtained from the same sample eluates used for MALDI MS 
profiling, by pooling 96 single ZipTip® eluates and using three different methods: (i) MALDI 
MS/MS, (ii) ESI MS/MS and (iii) off-line LC fractionation and ESI MS/MS with or without 
tryptic digestion.  Additional MALDI MS profiles were taken throughout the sample 
preparation after each essential step in order to link the MALDI MS profile peaks with the 
obtained peak identification. 
 
For peak identification using MALDI MS/MS, the pooled eluates were mixed in a ratio of 1:1 
(v:v) with either 5 mg/mL α-cyano-4-hydroxycinnamic acid (CHCA) or 50 mg/mL 2,5-
dihydroxybenzoic acid (DHB) matrix prepared in 50% acetonitrile (ACN) / 0.1% trifluoroacetic 
acid (TFA) and spotted onto a MALDI target plate for analysis on a Q-TOF Premier (Waters, 
Manchester, UK) equipped with a 337nm-UV-MALDI source. 
 
For peak identification using ESI MS/MS, the pooled eluates were first dried, then 
resuspended in 50% ACN / 0.1% formic acid (FA) and sprayed using a Nanomate HD 
(Advion Biosciences, Ithaca, USA) as nanoESI ion source in front of the Q-TOF Premier.  A 
positive voltage of 1.7 kV was applied to the chip and the flow rate was kept constant at 
about 80 nL/min.  At this flow rate, a sample volume of 10 µL provided stable static 
electrospray for at least 2 hrs. 
 
For peak identification using the more complex sample processing of off-line LC fractionation 
and ESI MS/MS, serum fractionation was first carried out, using an Agilent 1100 LC system 
(Agilent Technologies inc., Santa Clara, USA).  A volume of 100 µL of the pooled serum 
sample eluates was loaded onto a HiChrom ACE C18 column (2.1mm ID, 150 mm length) 
(HiChrom Ltd., Reading, UK).  The column was initially equilibrated with 5% ACN / 0.1% FA.  
The elution was achieved using a binary solvent gradient of 5% ACN / 0.1% FA to 70% ACN 
/ 0.1% FA at a flow rate of 100 µL/min over 90 min, and finally up to 95% ACN / 0.1% FA in 
10 min.  The UV detection was set at 214 nm and fractions were collected at a rate of 1 per 
minute.  The fractions were then dried and resuspended in 40 µL of 50% ACN / 0.1% FA.  
From each resuspended fraction a volume of 15 µL was taken for chip-based nanoESI 
analysis using the Nanomate and Q-TOF Premier, 2 µL were used for MALDI-TOF analysis 
using the Ultraflex and the remaining volume was dried before being resuspended with a 
15µL-trypsin solution (100 ng trypsin in 100 mM ammonium bicarbonate, pH 8.5).  The 
resuspended solutions were thoroughly mixed and incubated overnight at 37C.  Finally, the 
digested fractions were subjected to automatic cleaning using C18 ZipTips® according to the 
protocol detailed above for MALDI-TOF MS profiling except that the elution step which was 
performed using 10 µL of 50% ACN / 0.1% FA.  The purified digested fractions were then 
loaded on the Nanomate system and nanoESI MS/MS data were collected using data 
dependent acquisition.  Identification of peptides was performed by searching against the 
human protein sequence library in NCBInr (v20081128, 216937 sequences) using the 
Mascot search engine (Matrix Science, London, UK).  The searches were performed 
choosing “none” for digestion enzyme and with a mass tolerance of 0.1 Da for parent ions 
and 0.2 Da for fragment ions. “Ammonia-loss (N-term C)”, “Deamidated (NQ)”, “Dehydrated 
(N-term C)”, “Oxidation (M)”, “Phospho (ST)”, and “Phospho (Y)” were set as variable 
modifications. 
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GPMAW software v7.10 (Lighthouse data, Odense, Denmark) was used to match accurate 
mass data obtained from undigested samples with theoretical peptide masses of protein hits 
obtained from the MASCOT analysis of the MS/MS data of the digested fractions.  Isotope 
pattern software v3.0 (Bruker Daltonics) was used for the comparison of experimental 
isotopomer distributions with the theoretical distribution from putative peptide identifications 
and the UniProt and NCBI protein databases were used to extract additional information for 
substantiating or rejecting putative identities, e.g. information with regard to alternative 
splicing, prosequence cleavage, disulfide bridges and post-translational modifications. 
 
Results and Discussion 
MALDI-TOF MS profiling of 60 serum samples revealed 108 aligned peaks within the 
combined UKCTOCS and UKOPS serum sample set, using an S/N ratio above 5 
(Supplemental Table S1).  With the threshold set at S/N > 3, the number of common peaks 
was 156.  Despite the high number of common peaks, the different sample collection and 
handling protocols for the UKOPS and UKCTOCS sample sets resulted in markedly different 
MALDI MS profiles (Figure 1).  Most of the peak intensities of the 108 common peaks were 
significantly different between the UKCTOCS and UKOPS samples (Supplemental Table 
S1).  Thus, serum samples from both sample sets were employed in an effort to identify as 
many profile peaks as possible using the higher mass accuracy and sequencing capability of 
MALDI Q-TOF instrumentation. 
 
Many of the peak identifications were obtained by direct switching from MALDI MS to MALDI 
CID MS/MS, analysing the precursor ions determined in the MALDI MS profile.  This 
approach provided a total of 36 identities through MASCOT searching (Supplemental Table 
S2).  The average mass accuracy of the precursor ion mass measurements was 13 ppm.  
The next approach was using the same samples for nanoESI MS/MS analysis without 
complex sample processing such as enzymatic digestion or fractionation.  A straightforward 
change of the solvent system made the samples amenable for nanoESI analysis via direct 
infusion using the chip-based Nanomate system.  Similarly to the MALDI analysis, MS profile 
spectra were first acquired and MS/MS analysis of the precursor ions of the MS profile 
provided their identity.  In this approach, the MALDI and ESI MS profiles were compared to 
match peaks unambiguously and a total of 16 peaks were identified, of which 6 could not be 
identified by earlier MALDI MS/MS analysis. 
 
Next, the serum sample eluates were fractionated by off-line C18 reversed phase 
chromatography and the fractions were analysed by chip-based nanoESI as before.  
Although LC fractionation was employed, no further advanced sample processing was 
applied such as depletion or multi-dimensional separation strategies, which have been 
typically used in previous reports where 200 to 400 peptides were identified 13-15, 17.  In 
contrast to these reports, the objective of our fractionation strategy was to enhance mass 
spectrometric analysis of the profile peaks without changing the overall composition to a 
degree that would make the assignment of the identities too uncertain.  Thus, we also 
monitored the change of the MALDI MS profile after fractionation by comparing the pre-
fractionation MALDI MS profile with the MALDI MS (and ESI MS) profiles of each fraction.  
The fractions were then analysed by chip-based nanoESI MS/MS and the MS/MS data of 
each precursor ion was searched against the human subset of the NCBInr protein database 
using MASCOT, which resulted in an additional 28 identities and another 9 confirmations of 
identities obtained by the two earlier approaches without LC fractionation. 
 
Unfortunately for peaks above m/z 4,500, none of these approaches led to unambiguous 
peptide identification.  The collected LC fractions were therefore further processed by 
performing tryptic in-solution digestion with subsequent purification as employed for MALDI-
TOF MS profiling.  The digested fractions were analysed by chip-based nanoESI MS/MS 
and the MS/MS data of each fraction was combined and searched against the human subset 
of the NCBInr protein database using MASCOT.  For each fraction, the protein hits from 
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these searches were then used to search for peptide sequences with a theoretical mass that 
was within 50 ppm of the experimental value of the previously recorded profile peaks from 
the undigested fractions.  In addition, any putative matches were further interrogated by their 
isotopomer distribution, their known post-translational modifications and the likelihood of 
occurrence derived from their structural and functional information in protein databases.  For 
instance, any peptide sequences that stretched over a pro-sequence cleavage site were 
dismissed.  Where possible, fragment ion spectra from the previous methods were also used 
to substantiate putative identities.  Overall, this approach led to an additional 11 peak 
identities. 
 
In total, more than 80 polypeptides were identified with high confidence, representing 
peptides from 13 different but highly abundant proteins (see Supplemental Table S2).  
Among these there were three full length proteins, Apoliprotein CII (Apo CII), Apolipoprotein 
CIII (Apo CIII) and Connective tissue-activating peptide III (CTAP-III).  The peaks at m/z 
1547 and 1616 were clearly identified by both MALDI MS/MS and ESI MS/MS without LC 
fractionation, and correspond to Fibrinopeptide A fragments phosphorylated at serine (see 
Supplemental Figure S1).  Interestingly, many of the Fibrinopeptide A/B peaks and others 
show a loss of 17 Da (ammonia) and sometimes of water.  Some of the identified 
peptides/proteins were found to correspond to oxidised forms already identified.  These were 
excluded from the list since many of these did not appear in the MALDI MS profiles and were 
most likely products obtained from the sample handling.  This clearly shows that the MS 
peaks/profiles can substantially change with complex sample preparation methods, 
underlining the need for careful profile peak identification that is different to peptide 
identification of in-depth proteomic serum analyses. 
 
A detailed comparison of our peak list with the peak lists reported by Villanueva et al. 16 and 
Peng et al. 18 shows that the lists are complementary rather than redundant (see Figure 2 
and Table 1).  It is worth noting that although the number of identified peaks from this study 
is comparable to the number reported by Villaneuva et al. 16, only about 30% (25 peaks) are 
common between the two lists (Figure 2).  Furthermore, the present study was able to 
identify nine polypeptides in the mass range of 4 – 10 kDa, three times as many as reported 
so far.  However, within this mass range there were many more polypeptides for which the 
parent protein was identified after digestion but the data was inconclusive for assigning 
single identities to the MALDI MS profile peaks. 
 
A comparison with a list of plasma peptide identifications reported by Koomen et al. shows 
that again only about 30% (25 peaks) are common.  This, however, constitutes only about 
10% of the earlier published plasma peptide list which comprises 249 peptide identifications, 
reflecting the inherent difference between blood plasma and serum.  Interestingly, none of 
the identifications up to a mass of 1,200 Da are shared.  In the serum profiles, these are 
mostly Fibrinogen peptides.  The higher signal intensities of Fibrinogen peptides in serum 
profiles have been reported previously 19. 
 
Combining this peak list with the lists from Villanueva et al. 16 and Peng et al. 18 increases 
the number of identified polypeptides of MALDI MS serum profiles to 139.  This provides an 
extensive list of peptide identifications obtained from human blood serum that can be used 
for provisional identification of MALDI MS profiling peaks below 10 kDa through simple 
comparison.  Furthermore, this will allow, by quick comparison of MS profile and/or MS/MS 
data, the identification of many potential biomarkers commonly listed in reports without 
identification and thus, facilitate biomarker validation. 
  
MALDI and ESI MS/MS analysis of some of the MALDI MS profiling peaks resulted in 
MS/MS spectra different to those usually found for peptides (Figure S2).  These 
fragmentation spectra were typical for phospholipids and their identification was carried out 
by comparing their accurate masses (within 10 ppm) to the calculated masses obtained from 
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the LipidMaps database (www.lipidmaps.org).  The presence of ion fragments at m/z 86.10, 
104.11 and 184.07 in all MS/MS spectra is characteristic for choline, H2O-choline and 
phosphocholine, respectively (see Figure S2 and Table S3), and confirmed that these peaks 
are associated with phosphocholine lipids. 
 
Interestingly, a comparison with a recently published list of endogenous serum peptides that 
were obtained by extensive prefractionation and ESI-MS/MS shows that more than 40% of 
the fibrinogen (P02671) peptides in Table 1 were not identified despite the much higher 
number of identified peptides (>1000) obtained in that study20.  Other comparisons including 
lists of endogenous plasma peptides21 and other proteins showed similar results.  In 
addition, none of these lists include any post-translational modifications (PTMs), and only 
recently a few phosphorylated endogenous serum peptides were reported22.  The presented 
list is based on MALDI MS profile peak identification and as such includes PTMs as well as 
other non-peptidic components.  The focus on MALDI MS profile peak identification also 
provides an additional and decisive advantage.  While other lists might provide many more 
endogenous peptides, these are not linked to MALDI MS profiling.  As a result entries cannot 
be ranked according to their signal intensity in MALDI MS profiles and many of the entries 
will have the same mass value within a given mass tolerance.  For instance, the above 
comparison (based only on fibrinogen peptides) reveals that the profile peak at m/z 1518.7 
would have been wrongly assigned using the more extensive list of endogenous serum 
peptides published by Bakun et al.20.  In the latter, the peptide at the corresponding mass 
was identified as NRGDSTFESKSYK (cf. Table 1).  In the same list, there is no entry for the 
serine-phosphorylated peptide DSGEGDFLAEGGGV or for its associated peptide that has 
lost phosphoric acid, which has the same mass value as NRGDSTFESKSYK within a 
tolerance of 25ppm.  In addition, the peptide entries for the profile peak at m/z 1309.6 would 
have led to an ambiguous identification of either SSSYSKQFTSST or DSGEGDFLAEGGGV, 
again assuming a mass accuracy of around 25ppm or more.  Even at 10ppm most fibrinogen 
peptides are not unique for their respective mass value.  For instance, there are seven 
fibrinogen peptides with exactly the same m/z value of 1206.57.  The above analysis clearly 
shows that any list of endogenous serum peptides can only be useful for MALDI MS profiling 
if the peak identifications can be directly linked to the MALDI MS profiles. 
 
In conclusion, the dataset presented provides the identification of more than 90 serum 
MALDI MS profiling peaks with little overlap with already published datasets.  The more than 
80 identified polypeptides originate from only 13 proteins, mainly Fibrinogen alpha and beta 
chain (total of 48).  Complementary to other published lists this dataset also provides the 
identification of very low molecular weight (< 1 kDa) peaks often associated with 
phospholipids and peaks above 5 kDa.  Together with previously published data the most 
comprehensive MALDI MS serum profiling list consisting of 148 peak identifications is now 
available (see Table 1). 
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Legends 
Figure 1: 
Averaged MALDI-TOF mass spectra of human serum samples collected for UKCTOCS 
(upper panel) and UKOPS (lower panel) and obtained from purifications of 5μL-aliquots 
using pre-packed C18 ZipTips®. Averaged mass spectra were generated by ClinProTools 
software v2.1 after baseline subtraction, smoothing, normalisation and peak realignment. 
 
Figure 2: 
Venn diagram showing the number of overlapping and total number of peptides identified in 
this study and those of the studies of Villanueva et al. 16 and Peng et al. 18.  
 
Figure S1: 
Fragmentation mass spectra of the MALDI MS profile peaks at the average mass of 1466.51 
Da and 1617.55 Da acquired by MALDI MS/MS (a, b) and ESI MS/MS (c, d).  The MS/MS 
spectra were acquired using the precursor ion m/z value of 1465.66 and 1616.66 for MALDI, 
and 733.33 and 808.83 for ESI, respectively.  The peaks could be assigned to the following 
sequences from Fibrinopeptide A: DSGEGDFLAEGGGVR (a, c) and 
ADpSGEGDFLAEGGGVR (b, d) with Mowse scores of 72 (a), 83 (b), 88 (c) and 122 (d). 
 
Figure S2: 
MALDI MS/MS spectra of the precursor ions at m/z 991.67 and 1015.67, corresponding to 
phosphatidylcholine-containing phospholipids (see Supplemental Table S3 for details). 
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Table 1. List of MALDI MS profile peaks 
Calculated 
Monoisot. 
[M+H]+ 
Calculated 
Average 
[M+H]+  
Protein/Peptide or Lipid Peptide Sequences Identified Study 
UniProt 
Entry 
Name (Fragment)  
Tiss et 
al. 
Villanueva 
et al. 
Peng et 
al. 
445.2518 445.4944 P02671 FPA (12-16) E.GGGVR    
496.3426  NA PC(16:0/0:0) NA    
518.3236  NA PC(18:3/0:0) NA    
520.3393  NA PC(18:2/0:0) NA    
522.3590  NA PC(18:1/0:0) NA    
524.3742  NA PC(18:0/0:0) NA    
574.2944 574.6087 P02671 FPA (11-16) A.EGGGVR    
645.3315 645.6867 P02671 FPA (10-16) L.AEGGGVR    
740.2846 740.7172 P02675 FPB (1-7) – NH3 – H2O Q(-NH3)GVND(-H2O)NE.E    
758.4155 758.8522 P02671 FPA (9-16) F.LAEGGGVR    
758.5701  NA PC(16:0/18:2 or 18:0/16:2) NA    
760.5915  NA PC(16:0/18:1 or 18:0/16:1) NA    
822.4297 822.9731 P10909 Clusterin precursor (217-222) P.HFFFPK.S    
842.3944 842.9214 Q14624 ITIH4 (681-687) D.HAAYHPF.R    
864.4097 864.9299 P02671 FPA (7-15) D.DFLAEGGGV.R    
869.3272 869.8334 P02675 FPB (1-8) – NH3 – H2O Q(-NH3)GVND(-H2O)NEE.G    
904.4676 905.0324 P01042 Bradykinin (1-8) RPPGFSPF.R    
905.4839 906.0288 P02671 FPA (8-16) D.FLAEGGGVR    
920.4624 921.0385 P01042 Bradykinin (1-8) [Pro_Hydroxyl] RPPGFSP(Hydroxyl)F.R    
926.3486 926.8856 P02675 FPB (1-9) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEG.F    
942.4680 943.0358 P01024 Complement C3f fragment (9-16) I.HWESASLL.R    
944.3592 944.8817 P02675 FPB (1-9) – NH3 Q(-NH3)GVNDNEEG.F    
991.6807  NA PC(16:0/0:0) dimer NA    
998.4955 999.1075 Q14624 ITIH4 (681-688) D.HAAYHPFR.    
1015.6831  NA PC(16:0/0:0) + PC(18:2/0:0) dimer NA    
1020.5108 1021.1174 P02671 FPA (7-16) G.DFLAEGGGVR    
1055.5520 1056.1937 P01024 Complement C3f fragment (8-16) R.IHWESASLL.R    
1060.5787 1061.2185 P01042 Bradykinin RPPGFSPFR    
1073.4171 1074.0634 P02675 FPB (1-10) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEGF.F    
1076.5736 1077.2179 P01042 Bradykinin [Pro_Hydroxyl] RPPGFSP(Hydroxyl)FR    
1077.5323 1078.1693 P02671 FPA (6-16) E.GDFLAEGGGVR    
1091.4277 1092.0559 P02675 FPB (1-10) – NH3 Q(-NH3)GVNDNEEGF.F    
1108.4542 1109.1005 P02675 FPB (1-10) QGVNDNEEGF.F    
1194.5273 1195.2274 P02671 FPA (3-15) D.SGEGDFLAEGGGV.R    
1206.5749 1207.2848 P02671 FPA (5-16) G.EGDFLAEGGGVR    
1211.6531 1212.3798 P01024 Complement C3f fragment (7-16) H.RIHWESASLL.R    
1220.4855 1221.2413 P02675 FPB (1-11) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEGFF.S    
1238.4961 1239.2519 P02675 FPB (1-11) – NH3 Q(-NH3)GVNDNEEGFF.S    
1263.5963 1264.3367 P02671 FPA (4-16) S.GEGDFLAEGGGVR    
10 
 
1277.7153 1278.5258 P10909 Clusterin precursor (217-226) P.HFFFPKSRIV.R    
1309.5542 1310.3160 P02671 FPA (2-15) A.DSGEGDFLAEGGGV.R    
1325.5281 1326.3076 P02675 FPB (1-12) – NH3 Q(-NH3)GVNDNEEGFFS.A    
1348.7120 1349.5194 P01024 Complement C3f fragment (6-16) T.HRIHWESASLL.R    
1350.6284 1351.4149 P02671 FPA (3-16) D.SGEGDFLAEGGGVR    
1396.5652 1397.4098 P02675 FPB (1-13) – NH3 Q(-NH3)GVNDNEEGFFSA.R    
1447.6447 1448.4929 P02671 FPA (2-16) – H2O A.DS(-H2O)GEGDFLAEGGGVR    
1449.7597 1450.6235 P01024 Complement C3f fragment (5-16) I.THRIHWESASLL.R    
1465.6554 1466.5035 P02671 FPA (2-16) A.DSGEGDFLAEGGGVR    
1498.7873 1499.6562 P0C0L4 Complement C4-A (1337-1349) R.NGFKSHALQLNNR.Q    
1518.6818 1519.5717 P02671 FPA – H2O ADS(-H2O)GEGDFLAEGGGVR    
1530.8692 1531.8273 Q59FS1 IGIH4 R.RPHFFFPKSRIV.R    
1536.6924 1537.5823 P02671 FPA ADSGEGDFLAEGGGVR    
1542.5939 1543.4566 P02671 FGA chain (605-619) A.DEAGSEADHEGTHST.K     
1545.6000 1546.4482 P02671 FPA (2-16) + P A.DSpGEGDFLAEGGGVR    
1562.8438 1563.7813 P01024 Complement C3f fragment (4-16) K.ITHRIHWESASLL.R    
1616.6594 1617.5493 P02671 FPA + P ADSpGEGDFLAEGGGVR    
1626.8459 1627.7857 P0C0L4 Complement C4-A (1337-1350) R.NGFKSHALQLNNRQ.I    
1690.9387 1691.9540 P01024 Complement C3f fragment (3-16) S.KITHRIHWESASLL.R    
1739.9299 1740.9619 P0C0L4 Complement C4-A (1337-1351) R.NGFKSHALQLNNRQI.R    
1751.9187 1752.9510 P01024 Complement C3f fragment (1-15) .SSKITHRIHWESASL.L    
1762.9222 1763.9653 P0C0L4 Complement C4-A (1353-1368) R.GLEEELQFSLGSKINV.K    
1768.8236 1769.8406 P01024 Complement C3 (1322-1337) S.EETKENEGFTVTAEGK.G    
1771.8497 1772.8893 P06727 Apolipoprotein A-IV (288-303) K.SLAELGGHLDQQVEEF.R    
1777.9708 1779.0314 P01024 Complement C3f fragment (2-16) S.SKITHRIHWESASLL.R    
1786.8547 1787.9504 Q14624 ITIH4 (671-687) L.GLPGPPDVPDHAAYHPF.R    
1807.9297 1808.9884 P02647 Apolipoprotein A-I (149-163) A.ELQEGARQKLHELQE.K    
1847.8379 1848.8859 P02671 FGA chain (607-624) E.AGSEADHEGTHSTKRGHA.K    
1855.8555 1856.9375 P01024 Complement C3 (1321-1337) R.SEETKENEGFTVTAEGK.G    
1865.0028 1866.1295 P01024 Complement C3f fragment (1-16) SSKITHRIHWESASLL.R    
1883.8114 1884.8701 P02671 FGA chain (605-622) A.DEAGSEADHEGTHSTKRG.H     
1884.9899 1886.0639 P02671 FGA chain (606-622) D.HEGTHSTKRGHAKSRPV.R    
1896.0311 1897.1494 P0C0L4 Complement C4-A (1336-1351) G.RNGFKSHALQLNNRQI.R    
1927.9508 1929.0755 P06727 Apolipoprotein A-IV (288-304) K.SLAELGGHLDQQVEEFR.R    
1943.9080 1945.0261 P01042 HMW Kininogen (440-456) H.NLGHGHKHERDQGHGHQ.R    
1971.0433 1972.2228 P02647 Apolipoprotein A-I (251-267) K.VSFLSALEEYTKKLNTQ    
2008.0788 2009.3518 Q0P5N8 TMSB4X (31-47) K.PDMAEIEKFDKSKLKKT.E    
2010.9708 2012.2352 Q14624 ITIH4 (669-687) – NH3 R.Q(-NH3)LGLPGPPDVPDHAAYHPF.R    
2021.1039 2022.2950 P01024 Complement C3f fragment SSKITHRIHWESASLLR    
2027.9974 2029.2378 Q14624 ITIH4 (669-687) R.QLGLPGPPDVPDHAAYHPF.R    
2045.9172 2047.1100 P01042 HMW Kininogen (480-497) L.DDDLEHQGGHVLDHGHKH.K    
2053.0812 2054.2822 P02647 Apolipoprotein A-I (220-238) K.ATEHLSTLSEKAKPALEDL.R    
2067.1921 2068.4016 P02775 Platelet Basic Protein precursor (110-127) D.APRIKKIVQKKLAGDESAD    
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2091.9074 2093.0900 P02671 FGA chain (605-624) A.DEAGSEADHEGTHSTKRGHA.K    
2113.0771 2114.3166 Q0P5N8 TMSB4X (52-70) E.KNPLPSKETIEQEKQAGES    
2115.0512 2116.3462 Q14624 (ITIH4) (347-367) R.NVHSAGAAGSRMNFRPGVLSS.R    
2122.8618 2124.1563 P02671 FGA chain (600-619) K.SYKMADEAGSEADHEGTHST.K    
2127.0128 2128.2565 P01042 HMW Kininogen (458-477) R.GHGLGHGHEQQHGLGHGHKF.K    
2162.9445 2164.1688 P02671 FGA chain (604-624) M.ADEAGSEADHEGTHSTKRGHA.K    
2184.0985 2185.4238 Q14624 ITIH4 (669-688) R.QLGLPGPPDVPDHAAYHPFR.R    
2209.0619 2210.3192 P01042 HMW Kininogen (438-456) R.KHNLGHGHKHERDQGHGHQ.R    
2267.1891 2268.5127 P02649 Apolipoprotein E (212-232) A.TVGSLAGQPLQERAQAWGERL.R    
2271.1305 2272.5274 Q14624 ITIH4 (667-687) S.SRQLGLPGPPDVPDHAAYHPF.R    
2279.2718 2280.6046 P02775 Platelet Basic Protein precursor (108-127) D.PDAPRIKKIVQKKLAGDESAD    
2305.2034 2306.5524 P0C0L4 Complement C4-A (1353-1374) R.GLEEELQFSLGSKINVKVGGNS.K    
2353.1518 2354.5363 Q0P5N8 TMSB4X (50-70) – NH3 T.QEKN(-NH3)PLPSKETIEQEKQAGES    
2358.1626 2359.5787 Q14624 ITIH4 (666-687) S.SSRQLGLPGPPDVPDHAAYHPF.R    
2371.1624 2372.5469 Q0P5N8 TMSB4X (50-70) T.QEKN(deam)PLPSKETIEQEKQAGES    
2378.2098 2379.6342 P0C0L4 Complement C4-A (1429-1449) K.DDPDAPLQPVTPLQLFEGRRN.R    
2379.0371 2380.4173 P02671 FGA (577-597) S.SSYSKQFTSSTSYNRGDSTFE.S    
2409.2633 2410.6688 P02649 Apolipoprotein E (210-232) R.AATVGSLAGQPLQERAQAWGERL.R    
2451.2051 2452.6608 P02766 Transthyretin precursor (101-123) K.ALGISPFHEHAEVVFTANDSGPR.R    
2453.9610 2455.4140 Q0P5N8 TMSB4X (49-70) – NH3 E.TQ(-NH3)EKNPLPSKETIEQEKQAGES    
2464.0793 2465.5698 P02671 FGA chain (600-622) K.SYKMADEAGSEADHEGTHSTKRG.H    
2471.2260 2472.6679 Q0P5N8 TMSB4X (49-70) E.TQEKNPLPSKETIEQEKQAGES    
2508.3529 2509.7985 P06727 Apolipoprotein A-IV (256-278) R.ISASAEELRQRLAPLAEDVRGNL.K    
2544.2297 2545.6650 P02671 FGA chain (606-629) D.EAGSEADHEGTHSTKRGHAKSRPV.R    
2551.1769 2552.7529 P0C0L4 Complement C4-A (957-979) R.TLEIPGNSDPNMIPDGDFNSYVR.V    
2553.1012 2554.5991 P02671 FGA chain (576-598) K.SSSYSKQFTSSTSYNRGDSTFES.K    
2565.3644 2566.8549 P02649 Apolipoprotein E (210-233) R.AATVGSLAGQPLQERAQAWGERLR.A    
2567.3729 2568.9088 P02768 Albumin precursor (27-48) A.HKSEVAHRFKDLGEENFKALVL.I    
2582.3402 2583.9185 Q14624 ITIH4 (617-639) R.NVHSGSTFFKYYLQGAKIPKPEA.S    
2599.2635 2600.7734 P02647 Apolipoprotein A-IV (280-303) K.GNTEGLQKSLAELGGHLDQQVEEF.R    
2602.3107 2603.8204 P00488 Factor XIIIa (14-38) R.AVPPNNSNAAEDDLPTVELQGVVPR.G    
2627.3400 2628.9194  Q14624 ITIH4 (663-687) P.GVLSSRQLGLPGPPDVPDHAAYHPF.R    
2659.2567 2660.7791 P02671 FGA chain (605-629) A.DEAGSEADHEGTHSTKRGHAKSRPV.R     
2704.4516 2706.0385 P0C0L4 Complement C4-A (1353-1378) R.GLEEELQFSLGSKINVKVGGNSKGTL.K    
2724.3893 2726.0348 Q14624 ITIH4 (662-687) R.PGVLSSRQLGLPGPPDVPDHAAYHPF.R    
2753.4369 2755.1053 P02768 Albumin precursor (25-48) R.DAHKSEVAHRFKDLGEENFKALVL.I    
2755.3646 2756.9595 P06727 Apolipoprotein A-IV (280-304) K.GNTEGLQKSLAELGGHLDQQVEEFR.    
2768.2282 2769.8514 P02671 FGA chain (576-600) K.SSSYSKQFTSSTSYNRGDSTFESKS.Y    
2778.4520 2780.0741 P02654 Apolipoprotein C-I (29-53) P.DVSSALDKLKEFGNTLEDKARELIS.R    
2816.3234 2817.9581 P02671 FGA (548-574) R.GSESGIFTNTKESSSHHPGIAEFPSRG.K    
2829.4112 2831.0626 Q0P5N8 TMSB4X (46-70) K.KTETQEKNPLPSKETIEQEKQAGES    
2861.3343 2863.6505 P02671 FGA chain (603-629) K.MADEAGSEADHEGTHSTKRGHAKSRPV.R    
2931.2915 2933.0274 P02671 FGA chain precursor (576-601) K.SSSYSKQFTSSTSYNRGDSTFESKSY.K    
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2989.4292 2991.2246 P02671 FGA chain (602-629) Y.KMADEAGSEADHEGTHSTKRGHAKSRPV.R    
3156.6265 3158.5491 Q14624 ITIH4 (617-644) R.NVHSGSTFFKYYLQGAKIPKPEASFSPR.R    
3182.7347 3184.6627 P02647 Apolipoprotein A-I (240-267) R.QGLLPVLESFKVSFLSALEEYTKKLNTQ    
3190.4270 3192.3659 P02671 FGA (576-603) K.SSSYSKQFTSSTSYNRGDSTFESKSYKM.A    
3200.8001 3202.6864 P0C0L4 Complement C4-A (1353-1382) R.GLEEELQFSLGSKINVKVGGNSKGTLKVLR.T    
3206.4219 3208.3653 P02671 FGA (576-603) [Met-ox] K.SSSYSKQFTSSTSYNRGDSTFESKSYKMox.A    
3239.5246 3241.4788 P02671 FGA chain (600-629) K.SYKMADEAGSEADHEGTHSTKRGHAKSRPV.R    
3261.4641 3263.4440 P02671 FGA chain (576-604) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMA.D    
3272.6422 3274.6954 Q14624 ITIH4 (658-687) R.MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R    
3277.4590 3279.4434 P02671 FGA (576-604) [Met-ox] K.SSSYSKQFTSSTSYNRGDSTFESKSYKMoxA.D    
3377.7230 3379.7435 P02647 Apolipoprotein A-I (148-176) R.AELQEGARQKLHELQEKLSPLGEEMoxRDRA.R    
3675.9075 3678.0877 Q0P5N8 TMSB4X (39-70) K.FDKSKLKKTETQEKNPLPSKETIEQEKQAGES    
3953.9098 3956.4034 Q14624 ITIH4 (645-681) R.RGWNRQAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDH.A    
3970.9882 3973.4255 Q14624 (ITIH4) (650-687) R.QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R    
4280.1319 4282.7883 Q59FS1 IGIH4 (602-642) R.NVHSAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R    
4961.3111 4964.3899 P02671 FGA chain (529-574) or (513-558) T.FPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRG.K  or  
R.HPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTK.E 
   
5334.3536 5337.5402 P02671 FGA chain (577-624) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHA.K    
5901.7029 5905.2293 P02671 FGA chain (577-629) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R    
6627.3167 6631.4463 P02655 Apoliporotein C-II (32-90) M.PSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIFT.D    
8200.0508 8205.1815 P02655 Apoliporotein C-II (29-101) Q.DEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIF
TDQVLSVLKGEE 
   
8760.2248 8765.6732 P02656 Apolipoprotein C-III SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSE
FWDLDPEVRPTSAVAA 
   
8910.3855 8915.9261 P02655 Apoliporotein C-II (Chain A) TQQPQQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTY
TGIFTDQVLSVLKGEE 
   
9282.8208 9288.7182 P02775 CTAP-III NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICL
DPDAPRIKKIVQKKLAGDESAD 
   
* In the MS/MS spectra of these peaks, Choline, H2O-Choline and PhosphoCholine peaks were dominant but no corresponding phospholipids 
were found in the LipidMaps database. 
CTAP-III: Connective tissue-activating peptide III; FGA: Fibrinogen alpha; FPA: Fibrinopeptide A; FPB: Fibrinopeptide B; HMW Kininogen: 
High molecular weight kininogen; IGIH4: Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) varaint; ITIH4: Inter-
alpha-trypsin inhibitor heavy chain H4; NA: Not applicable; PC: Phophatidylcholine; TMSB4X: Thymosin, beta 4.  [M+H]+ values were 
calculated using IsotopePattern Software (Bruker Daltonics). 
